Drugs / ropivicaine 0.2%
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04080739 | Jan 2020 → Mar 2022 | — | University of Alabama at Birmingham | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ropivicaine 0.2% | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04080739 ↗ |
| Route | Other | “2-8 cc/hr of 0.2% ropivicaine given as a regional block via US-guided ipsilateral sciatic nerve block for fibula free flap patients or US-guided infraclavicular brachial plexus...” NCT04080739 ↗ |